🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Oregon

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Oregon

26 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Oregon.

Mga Lungsod sa Oregon

Opisyal na teksto ng pag-aaral (English)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Providence Newberg Medical Center, Newberg
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Willamette Falls Medical Center, Oregon City
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Willamette Valley Cancer Institute, Eugene
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT05554406

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • at 7 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Providence Newberg Medical Center, Newberg
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Willamette Falls Medical Center, Oregon City
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05564390

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT05429632

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT05554393

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT07228273

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Oregon Health & Science University, Portland
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT04065399

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Oregon Health and Science University, Portland
  • Oregon Oncology Specialists, Salem
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT04256317

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07548983

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03874052

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06504459

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • Oregon Health and Science University, Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT03471260

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Portland OR-OHSU, Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT04659616

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Oregon Health and Science University, Portland
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06357182

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Oncology Associates of Oregon, Eugene
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • OHSU, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Oregon Health & Science University, Portland
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 25, 2025 · NCT05237258

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.